Current stock page

Catalysts

IDYA Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

IDYAIDEAYA Biosciences, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$31.83+$0.34 (+1.08%)

Latest quote

  • Momentum
    63
  • Value
    39
  • Quality
    51
  • Risk resilience
    61
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 16, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 54/100

Momentum 63/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 21.64%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 63/100AIQ Edge 5/10 In Line With Peers
Beat rate
25%
2 of 8 reported periods
Average surprise
+10.5%
Across covered historical reports
Latest result
-3.4%
Nov 3, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 3, 2026—-$1.18-$1.22-3.4%$7.58M$10.24M
Aug 4, 2026—-$1.06-$1.22-15.1%$8.02M$8.86M
May 5, 2026—-$1.07-$1.11-3.7%$5.04M$6.56M
Feb 17, 2026—-$0.95-$0.94+1.2%$6.31M$10.88M
Nov 4, 2025—-$0.95$1.33+240.6%$5.95M$207.83M
Aug 5, 2025—-$0.85-$0.88-3.5%$2M—
May 6, 2025—-$0.75-$0.82-9.3%$2.4M—
Feb 13, 2025—-$0.67-$1.49-122.4%$2.5M$7M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
15
Buy
1
Hold
12-month analyst target
$48.75
+53.16% versus current price
Based on 16 analyst observations. Targets are estimates, not predictions.
Low target
$39.00
+22.53% vs latest price
Average target
$48.75
+53.16% vs latest price
High target
$57.00
+79.08% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 16, 2027

Next known earnings or reporting date.

EPS estimate-$1.18

Current analyst expectation for the upcoming report.

Revenue estimate$18.85M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score63

Where event reaction would show up first.

AIQ score54/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
16
Average target
$48.75
Target upside
53.16%
Target range
$39.00 - $57.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
zacks.com · Oct 27, 2026

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

gurufocus.com · Oct 19, 2026

Ideaya Biosciences (IDYA) to Present New Darovasertib Trial Data at ESMO Congress 2026

On October 19, 2026, Ideaya Biosciences Inc (NASDAQ: IDYA) announced it will unveil updated clinical results from three ongoing trials evaluating darovasertib f

gurufocus.com · Oct 16, 2026

IDYA Initiates Coverage On by William Blair -- Rating Set at Outperform

IDEAYA Biosciences (IDYA) Analyst Rating Update On October 16, 2026, William Blair has initiated coverage on IDEAYA Biosciences (IDYA) with a rating of Outpe

insidermonkey.com · Sep 25, 2026

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical...

seekingalpha.com · Sep 14, 2026

IDEAYA Biosciences, Inc. (IDYA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

IDEAYA Biosciences, Inc. (IDYA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:00 AM EDTCompany ParticipantsYujiro Hata -...

Open full news and sentiment

IDYA Catalysts FAQ

What are the next catalysts for IDYA stock?

IDYA's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move IDYA stock?

Upcoming events that could move IDYA include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could IDYA's next earnings report affect the stock?

IDYA's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive IDYA stock higher?

IDYA could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt IDYA stock?

IDYA could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.